Company: INTS
Filing Date: 2025-06-12
Form Type: 424B5
Source: 0001628280-25-031040
Chunk: 0

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-06-12
Form: 424B5
Chunk 0
---
| Filed pursuant to Rule 424(b)(5) 
 Registration No. 333-280681      |

#### PROSPECTUS SUPPLEMENT
(To Prospectus Dated July 11, 2024)

#### 6,675,000 Shares of

#### Common Stock

#### Intensity Therapeutics, Inc.
We are offering shares of our common stock par value $0.0001 per share, pursuant to this prospectus supplement and the accompanying prospectus. The shares will be sold for a purchase price of $0.30 per share.

Our common stock is listed on The Nasdaq Capital Market under the symbol “INTS”. On June 11, 2025, the last reported sale price of our common stock on Nasdaq was $0.579 per share.

As of the date of this prospectus supplement, the aggregate market value of our outstanding shares of common stock held by non-affiliates, or public float, was determined to be $27,005,378 based on 13,920,928 shares of common stock outstanding held by non-affiliates, and the closing sale price of our shares of common stock on Nasdaq of $1.94 on April 21, 2025, which is within 60 days of the date of this prospectus supplement. Upon any sale of shares of common stock under this prospectus supplement pursuant to General Instruction I.B.6 of Form S-3, in no event will the aggregate market value of securities sold by us or on our behalf pursuant to General Instruction I.B.6 of Form S-3 during the twelve calendar month period immediately prior to, and including, the date of any such sale exceed one-third of the aggregate market value of our shares of common stock held by non-affiliates, calculated in accordance with General Instruction I.B.6 of Form S-3. During the prior 12 calendar month period that ends on, and includes, the date of this prospectus supplement (excluding this offering), we have sold $3,577,830 of our securities pursuant to General Instruction I.B.6 of Form S-3.

Investing in our securities involves significant risks. Please read the information contained in or incorporated by reference under the heading “

#### Risk Factors

#### ” beginning on page

#### S- 9
of this prospectus supplement, and under similar headings in other documents filed after the date hereof and incorporated by reference into this prospectus supplement and the accompanying prospectus.

Neither the Securities and Exchange Commission nor